Elon Musk's Drug Use Puts Tesla Board in Quandary

Board members face potential financial and legal risks as they decide how to handle the CEO's reported drug use.

Elon Musk's reported recreational drug use and ongoing consumption of ketamine has put Tesla's board in a familiar position of deciding how to handle the CEO's actions that could potentially expose the company to financial and legal risks.
Several board members had recently agreed to return $735 million to settle a lawsuit alleging they had excessively compensated themselves.
Shareholders have previously expressed dissatisfaction with the board over Tesla's succession planning and accused Musk of being distracted by his commitments to other companies.
Musk's drug use could potentially harm his other enterprises, particularly Space Exploration Technologies Corp., a US government contractor.
Musk's shares and exercisable stock options in Tesla are worth $97.6 billion, or about 44% of his $219.4 billion net worth.